Metformina + Vildagliptina Zentiva (Metformin Hydrochloride, Vildagliptin)

Metformin Hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, which reduces the amount of glucose released by the liver. It also increases peripheral tissue sensitivity to insulin, allowing cells to take up glucose more efficiently, thereby contributing to overall glycaemic reduction.

The exact dose is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, renal function, and response to therapy. Healthcare professionals adjust the amount and frequency to achieve target blood‑glucose levels while minimizing adverse effects.

Safety data for Metformina + Vildagliptina in pregnancy and lactation are limited. The product is generally not recommended for use unless the potential benefit justifies the possible risk to the fetus or infant. Physicians should discuss alternatives and weigh risks before prescribing.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina + Vildagliptina combines a biguanide with a DPP‑4 inhibitor, offering dual mechanisms that address both basal and post‑prandial glucose. Compared with metformin plus a sulfonylurea, the DPP‑4 inhibitor carries a lower risk of hypoglycaemia and weight gain, while providing comparable efficacy in many patients.

The tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Metformina + Vildagliptina is taken orally, usually with meals to reduce gastrointestinal discomfort. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider. Consistent timing with meals helps maintain stable drug levels.

The most severe adverse events include lactic acidosis, which can be life‑threatening, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), and acute pancreatitis. Prompt medical attention is required if patients experience unexplained abdominal pain, rapid breathing, or signs of metabolic acidosis.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or vildagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis should avoid this medication. Clinicians must also assess liver disease and contraindications before prescribing.